Grand Pharmaceutical Group Valuation

Q: What is the Fair Price of MX6A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MX6A (€0.51) is trading below our estimate of [[fair value]] (€1.33)

Is MX6A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MX6A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MX6A (€0.51) is trading below our estimate of fair value (€1.33)

Significantly Below Fair Value: MX6A is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MX6A?

Key metric: As MX6A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MX6A. This is calculated by dividing MX6A's market cap by their current earnings.
What is MX6A's PE Ratio?
PE Ratio	6.3x
Earnings	HK$2.41b
Market Cap	HK$15.20b

MX6A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	4.9x
PEG Ratio	2.8x

Price to Earnings Ratio vs Peers

How does MX6A's PE Ratio compare to its peers?

The above table shows the PE ratio for MX6A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.6x
DMP Dermapharm Holding	22.3x	18.1%	€2.0b
PSG PharmaSGP Holding	15.4x	13.9%	€280.6m
2FJ0 Pierrel	29.9x	n/a	€92.8m
MRK Merck KGaA	22.9x	10.9%	€61.6b
MX6A Grand Pharmaceutical Group	6.3x	2.3%	€15.2b

Price-To-Earnings vs Peers: MX6A is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (22.6x).

Price to Earnings Ratio vs Industry

How does MX6A's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: MX6A is good value based on its Price-To-Earnings Ratio (6.3x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is MX6A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MX6A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.3x
Fair PE Ratio	13.4x

Price-To-Earnings vs Fair Ratio: MX6A is good value based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (13.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MX6A forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€0.51	€0.69 +36.9%	6.9%	€0.74	€0.64	n/a	2
Nov ’25	€0.52	€0.69 +34.2%	6.9%	€0.74	€0.64	n/a	2
Oct ’25	€0.57	€0.76 +34.0%	16.9%	€0.89	€0.63	n/a	2
Sep ’25	€0.49	€0.76 +57.2%	16.9%	€0.89	€0.63	n/a	2
Aug ’25	€0.50	€0.76 +54.0%	16.9%	€0.89	€0.63	n/a	2
Nov ’24	€0.49	€0.93 +90.7%	4.3%	€0.97	€0.89	€0.52	2
Oct ’24	€0.50	€0.93 +86.8%	4.3%	€0.97	€0.89	€0.57	2
Sep ’24	€0.45	€0.93 +105.8%	4.3%	€0.97	€0.89	€0.49	2
Aug ’24	€0.51	€0.93 +84.2%	4.3%	€0.97	€0.89	€0.50	2
Jul ’24	€0.52	€0.93 +80.7%	4.3%	€0.97	€0.89	€0.53	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Fortrea Holdings

US$1.8b

A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.

K67

US$18.40

2.8%

-38.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

1.3%

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

3.6%

22.9%